Publication date: Dec 02, 2019
Intentional suspected suicide attempts increased by 80. 3% for isolated gabapentin exposures over a five-year-period and 43% for baclofen over a four-year-period A major new analysis of the non-opioid medications, gabapentin and baclofen, shows “worrying” increases in related suicide attempts and hospital admissions in US adults since 2013 – coinciding with a decrease in opioid prescriptions.
In this latest study, published in Clinical Toxicology, researchers from the University of Pittsburgh looked at over 90,000 cases of exposure to the medications and saw large increases in misuse and toxicity – with isolated abuse instances of using gabapentin (from 2013 to 2017) rising by 119. 9%, and baclofen (2014-2017) 31. 7%.
Intentional suspected suicide attempts increased by 80. 3% for isolated gabapentin exposures over a five-year-period and 43% for baclofen over a four-year-period.
Lead author Kimberly Reynolds, of the University of Pittsburgh, said: “We are seeing a worrying increase in harmful exposures to gabapentin and baclofen in US adults over recent years, which may be an unintended consequence of the move away from opioid prescriptions for pain management.
|disease||MESH||substance use disorders|
- Association Between Diagnoses of Chronic Noncancer Pain, Substance Use Disorder, and HIV-Related Outcomes in People Living With HIV.
- The effectiveness of prescription drug monitoring programs at reducing opioid-related harms and consequences: a systematic review.
- Relieving acute pain (RAP) study: a proof-of-concept protocol for a randomised, double-blind, placebo-controlled trial.